Login to Your Account

Cubist Gets Option To Acquire Illumigen; Funds HCV Drug

By Trista Morrison

Thursday, October 18, 2007
Cubist Pharmaceuticals Inc. moved to expand its pipeline beyond Cubicin (daptomycin for injection) by picking up an exclusive option to acquire Illumigen Biosciences Inc. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription